Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Financial Statements
- Click here to download Gilead Sciences, Inc.'s Income Statement
- Click here to download Gilead Sciences, Inc.'s Balance Sheet
- Click here to download Gilead Sciences, Inc.'s Statement of Cash Flows
Key Info
- Industry: Biological Product (except Diagnostic) Manufacturing
- Sector: Manufacturing
- CEO Name: Daniel O'Day
Key Statistics
- Stock Price: $74.94
- Dividend Yield: 3.9%
- Market Capitalization: $93,376,315,614
- Shares Outstanding: 1,246,014,353
- Number of Employees: 17,000
- Trailing 12-Month EPS: $4.35
- Trailing 12-Month DPS: $2.9
- Payout Ratio: 66.7%
Important Dates
- Next Earnings Date: 2023-10-26
- Next Ex-Dividend Date: 2023-09-14
Price Trends
- Current Stock Price: $74.94
- 52-week high: $85.09
- 52-week low: $58.07
- 200-day moving average: $76.4
- 50-day moving average: $75.39
Performance
- 1-Month Price Return: -2.3%
- 3-Month Price Return: 0.5%
- 6-Month Price Return: -4.2%
- 1-Year Price Return: 25.7%
- 2-Year Price Return: 17.1%
- 5-Year Price Return: 21.0%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast